APLS
Price
$19.61
Change
+$0.07 (+0.36%)
Updated
Nov 21 closing price
Capitalization
2.48B
102 days until earnings call
Intraday BUY SELL Signals
RCUS
Price
$22.05
Change
+$0.82 (+3.86%)
Updated
Nov 21 closing price
Capitalization
2.73B
94 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

APLS vs RCUS

Header iconAPLS vs RCUS Comparison
Open Charts APLS vs RCUSBanner chart's image
Apellis Pharmaceuticals
Price$19.61
Change+$0.07 (+0.36%)
Volume$1.45M
Capitalization2.48B
Arcus Biosciences
Price$22.05
Change+$0.82 (+3.86%)
Volume$2.03M
Capitalization2.73B
APLS vs RCUS Comparison Chart in %
APLS
Daily Signal:
Gain/Loss:
RCUS
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
APLS vs. RCUS commentary
Nov 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APLS is a Hold and RCUS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 23, 2025
Stock price -- (APLS: $19.61 vs. RCUS: $22.05)
Brand notoriety: APLS and RCUS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APLS: 56% vs. RCUS: 133%
Market capitalization -- APLS: $2.48B vs. RCUS: $2.73B
APLS [@Biotechnology] is valued at $2.48B. RCUS’s [@Biotechnology] market capitalization is $2.73B. The market cap for tickers in the [@Biotechnology] industry ranges from $108.28B to $0. The average market capitalization across the [@Biotechnology] industry is $2.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APLS’s FA Score shows that 0 FA rating(s) are green whileRCUS’s FA Score has 0 green FA rating(s).

  • APLS’s FA Score: 0 green, 5 red.
  • RCUS’s FA Score: 0 green, 5 red.
According to our system of comparison, APLS is a better buy in the long-term than RCUS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APLS’s TA Score shows that 6 TA indicator(s) are bullish while RCUS’s TA Score has 3 bullish TA indicator(s).

  • APLS’s TA Score: 6 bullish, 4 bearish.
  • RCUS’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, APLS is a better buy in the short-term than RCUS.

Price Growth

APLS (@Biotechnology) experienced а -3.54% price change this week, while RCUS (@Biotechnology) price change was +9.87% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.01%. For the same industry, the average monthly price growth was -3.31%, and the average quarterly price growth was +62.87%.

Reported Earning Dates

APLS is expected to report earnings on Mar 04, 2026.

RCUS is expected to report earnings on Feb 25, 2026.

Industries' Descriptions

@Biotechnology (-1.01% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RCUS($2.73B) has a higher market cap than APLS($2.48B). RCUS YTD gains are higher at: 48.086 vs. APLS (-38.546). APLS has higher annual earnings (EBITDA): 93.4M vs. RCUS (-323M). RCUS has more cash in the bank: 831M vs. APLS (479M). RCUS has less debt than APLS: RCUS (111M) vs APLS (475M). APLS has higher revenues than RCUS: APLS (1.02B) vs RCUS (240M).
APLSRCUSAPLS / RCUS
Capitalization2.48B2.73B91%
EBITDA93.4M-323M-29%
Gain YTD-38.54648.086-80%
P/E Ratio54.47N/A-
Revenue1.02B240M423%
Total Cash479M831M58%
Total Debt475M111M428%
FUNDAMENTALS RATINGS
APLS vs RCUS: Fundamental Ratings
APLS
RCUS
OUTLOOK RATING
1..100
6589
VALUATION
overvalued / fair valued / undervalued
1..100
83
Overvalued
66
Overvalued
PROFIT vs RISK RATING
1..100
10096
SMR RATING
1..100
5596
PRICE GROWTH RATING
1..100
6535
P/E GROWTH RATING
1..100
5098
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RCUS's Valuation (66) in the Pharmaceuticals Major industry is in the same range as APLS (83) in the Medical Distributors industry. This means that RCUS’s stock grew similarly to APLS’s over the last 12 months.

RCUS's Profit vs Risk Rating (96) in the Pharmaceuticals Major industry is in the same range as APLS (100) in the Medical Distributors industry. This means that RCUS’s stock grew similarly to APLS’s over the last 12 months.

APLS's SMR Rating (55) in the Medical Distributors industry is somewhat better than the same rating for RCUS (96) in the Pharmaceuticals Major industry. This means that APLS’s stock grew somewhat faster than RCUS’s over the last 12 months.

RCUS's Price Growth Rating (35) in the Pharmaceuticals Major industry is in the same range as APLS (65) in the Medical Distributors industry. This means that RCUS’s stock grew similarly to APLS’s over the last 12 months.

APLS's P/E Growth Rating (50) in the Medical Distributors industry is somewhat better than the same rating for RCUS (98) in the Pharmaceuticals Major industry. This means that APLS’s stock grew somewhat faster than RCUS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APLSRCUS
RSI
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
87%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
81%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
81%
Declines
ODDS (%)
Bearish Trend 4 days ago
80%
Bearish Trend 10 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
APLS
Daily Signal:
Gain/Loss:
RCUS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SSHFX42.150.81
+1.96%
Sound Shore Investor
BBIEX15.160.27
+1.81%
Bridge Builder International Equity
GXXIX13.830.16
+1.17%
abrdn US Sustainable Leaders InstlSvc
ISCSX16.570.16
+0.98%
VY® Columbia Contrarian Core S
JHTAX20.420.18
+0.89%
JPMorgan Hedged Equity 3 A

APLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, APLS has been loosely correlated with NEVPF. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if APLS jumps, then NEVPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APLS
1D Price
Change %
APLS100%
+0.36%
NEVPF - APLS
41%
Loosely correlated
N/A
DNLI - APLS
39%
Loosely correlated
+4.90%
VNDA - APLS
39%
Loosely correlated
-0.83%
NUVL - APLS
38%
Loosely correlated
-1.97%
IMVT - APLS
38%
Loosely correlated
-0.88%
More